Fexofenadine
跳至導覽
跳至搜尋
Clinical data | |
---|---|
Trade names | Allegra, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a697035 |
data |
|
Pregnancy category | |
Routes of administration | By mouth |
Drug class | Antihistamine; H1 receptor antagonist |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 30–41%[9] |
Protein binding | 60–70%[8] |
Metabolism | Hepatic (≤5% of dose)[8] |
Elimination half-life | 14.4 hours |
Excretion | Feces (~80%) and urine (~10%) as unchanged drug[8] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C32H39NO4 |
Molar mass | 501.67 g͘mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
Fexofenadinen (
註解 [修改]
- ↑ "Fexofenadine Use During Pregnancy". Drugs.com. 1 April 2019. 26 July 2020 khòaⁿ--ê.
- ↑ "Telfast 30mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 25 October 2019. 20 June 2021 khòaⁿ--ê.
- ↑ "Almerg 180 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 20 June 2021 khòaⁿ--ê.
- ↑ "Fexofenadine Hydrochloride 120 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 22 March 2021. 20 June 2021 khòaⁿ--ê.
- ↑ "Allegra (fexofenadine hydrochloride) tablet, orally disintegrating for oral use Allegra (fexofenadine hydrochloride) tablet, film coated for oral use Allegra (fexofenadine hydrochloride) suspension for oral useInitial U.S。 Approval: 1996". DailyMed. 15 December 2008. 13 February 2022 khòaⁿ--ê.
- ↑ "Allegra Allergy- fexofenadine hydrochloride tablet, coated". DailyMed. 12 February 2022 khòaⁿ--ê.
- ↑ http://products.sanofi.ca/en/allegra.pdf [bare URL PDF]
- ↑ 8.0 8.1 8.2 Smith, SM; Gums, JG (July 2009). "Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders". Expert Opinion on Drug Metabolism & Toxicology. 5 (7): 813–22. doi:10.1517/17425250903044967. PMID 19545214.
- ↑ Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C (May 2010). "Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability". Eur J Pharm Sci. 40 (2): 125–31. doi:10.1016/j.ejps.2010.03.009. PMID 20307657.
- ↑ "Fexofenadine - international brand names". Drugs.com. 18 January 2017 khòaⁿ--ê.
- ↑ Bachert, C (May 2009). "A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis". Clin Ther. 31 (5): 921–44. doi:10.1016/j.clinthera.2009.05.017. PMID 19539095.
參閱 [修改]
- Pang-bô͘:Ill (
間仔 多 無人機 ) - Pang-bô͘:Ill (
排懷 行 武器 /Loitering munition/排懷行但藥 ) - Pang-bô͘:Ill (Texas Department of Family and Protective Services)
- Pang-bô͘:Ill
- Pang-bô͘:Ill (
過敏政 稱 tuañ/List of allergens)
外部 lên-ket[修改]
- "Fexofenadine". Drug Information Portal. U.S。 National Library of Medicine.
- "Fexofenadine hydrochloride". Drug Information Portal. U.S。 National Library of Medicine.
Lūi-pia̍t:
- All articles with bare URLs for citations
- Articles with bare URLs for citations from March 2022
- Articles with invalid date parameter in template
- Articles with PDF format bare URLs for citations
- Multiple chemicals in Infobox drug
- Chemicals using indexlabels
- Drug has EMA link
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Benzhydryl compounds
- Carboxylic acids
- Diols
- H1 receptor antagonists
- Peripherally selective drugs
- Piperidines
- Sanofi
- Sè-kài ōe-seng cho͘-chit ki-pún io̍h-bu̍t